Get the Stockscreener App
3.38
6.63%
-0.24
After Hours:
3.38
Camp 4 Therapeutics Corp stock is traded at $3.38, with a volume of 157.77K.
It is down -6.63% in the last 24 hours and up +4.00% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$3.62
Open:
$3.52
24h Volume:
157.77K
Relative Volume:
0.20
Market Cap:
$68.14M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-0.8252
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
+2.74%
1M Performance:
+4.00%
6M Performance:
+89.89%
1Y Performance:
-65.33%
1-Day Range:
$3.31
$3.6038
1-Week Range:
$3.11
$3.83
52-Week Range:
$1.305
$12.26
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.38 | 72.98M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
How Camp4 Therapeutics Corporation stock reacts to global recession fears2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Risk adjusted return profile for Camp4 Therapeutics Corporation analyzedJuly 2025 Trade Ideas & Entry Point Confirmation Signals - newser.com
Is Camp4 Therapeutics Corporation a good long term investmentCup and Handle Formations & Low Entry Investment Portfolio - earlytimes.in
Combining price and volume data for Camp4 Therapeutics CorporationShort Setup & Technical Analysis for Trade Confirmation - newser.com
Can Camp4 Therapeutics Corporation stock reach $100 price targetPortfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
Will Camp4 Therapeutics Corporation continue its uptrendPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
CAMP4 Therapeutics stock soars after $100 million private placement By Investing.com - Investing.com Nigeria
CAMP4 Aims For The Summit: Unlocking The Therapeutic Power Of RegRNA, Once Deemed Undruggable - RTTNews
Camp4 Therapeutics Corporation Stock Analysis and ForecastSector Performance Review & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating - Investing.com
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy By Investing.com - Investing.com Nigeria
Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01 - MarketScreener
CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - TipRanks
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy - Investing.com India
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewswire
Potential Breakthrough for Rare Brain Disorder: CAMP4's SYNGAP1 Drug Enters Final Pre-Clinical Stage - Stock Titan
What analysts say about Camp4 Therapeutics Corporation stockReal Estate Investment Trusts & These 3 Stocks Could Change Your Portfolio - Early Times
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Price action breakdown for Camp4 Therapeutics CorporationWeekly Trend Summary & Technical Entry and Exit Alerts - newser.com
What’s next for Camp4 Therapeutics Corporation stock priceWeekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Is Camp4 Therapeutics Corporation reversing from oversold territoryJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Applying chart zones and confluence areas to Camp4 Therapeutics CorporationMarket Growth Report & Free Long-Term Investment Growth Plans - newser.com
Backtesting results for Camp4 Therapeutics Corporation trading strategiesVolume Spike & Real-Time Volume Analysis Alerts - newser.com
How institutional ownership impacts Camp4 Therapeutics Corporation stockChart Signals & Safe Entry Momentum Tips - newser.com
Building trade automation scripts for Camp4 Therapeutics CorporationOptions Play & Consistent Profit Focused Trading Strategies - newser.com
Aug Spikes: Whats the beta of LILAK stockJuly 2025 Movers & Verified Momentum Stock Ideas - khodrobank.com
Trend analysis for Camp4 Therapeutics Corporation this weekCPI Data & High Return Stock Watch Alerts - newser.com
Analyzing Camp4 Therapeutics Corporation with multi timeframe chartsWeekly Trade Recap & Breakout Confirmation Alerts - newser.com
Aug Movers: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Trading Recap & Real-Time Stock Entry Alerts - خودرو بانک
Patterns Watch: What are Camp4 Therapeutics Corporation’s recent SEC filings showingOptions Play & High Accuracy Swing Entry Alerts - khodrobank.com
Using AI based signals to follow Camp4 Therapeutics CorporationM&A Rumor & AI Optimized Trade Strategies - newser.com
Earnings Recap: Can ProShares Trust ProShares UltraShort SmallCap600 beat the S&P 500Quarterly Market Summary & Weekly High Return Stock Forecasts - خودرو بانک
Support Test: Is Camp4 Therapeutics Corporation likely to announce a buybackJuly 2025 Gainers & Weekly Consistent Profit Watchlists - خودرو بانک
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
| Northpond Ventures II GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
763,636 |
8,399,996 |
763,636 |
| AH Equity Partners Bio I, L.L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
727,272 |
7,999,992 |
1,579,885 |
| Enavate Sciences GP, LLC | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
1,363,636 |
14,999,996 |
3,785,802 |
| Polaris Management Co. VII, L. | 10% Owner |
Oct 15 '24 |
Buy |
11.00 |
909,090 |
9,999,990 |
909,090 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):